(4Z)-4-[[2-methoxy-5-methyl-4-(methylsulfamoyl)phenyl]hydrazinylidene]-3-oxo-N-(2-oxo-1,3-dihydrobenzimidazol-5-yl)naphthalene-2-carboxamide CAS.NO:51920-12-8

We are (4Z)-4-[[2-methoxy-5-methyl-4-(methylsulfamoyl)phenyl]hydrazinylidene]-3-oxo-N-(2-oxo-1,3-dihydrobenzimidazol-5-yl)naphthalene-2-carboxamide CAS.NO:51920-12-8 CAS:51920-12-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: (4Z)-4-[[2-methoxy-5-methyl-4-(methylsulfamoyl)phenyl]hydrazinylidene]-3-oxo-N-(2-oxo-1,3-dihydrobenzimidazol-5-yl)naphthalene-2-carboxamide
CAS.NO:51920-12-8
Molecular Formula:C27H24N6O6S
Molecular Weight:560.58100
 
Physical and Chemical Properties:
Density:1.3-1.4 g/cm3
Boiling point:/
Melting point:335-345ºC
Flash point:/
Index of Refraction:1.722
 
Specification:
Appearance:Red powder
Purity:≥99.0%
 
Packing: 25kg drum
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Flammables-area.
Application:High-grade exterior paint, car original paint and repair paint, plastic, ink, rubber, etc.

(4Z)-4-[[2-methoxy-5-methyl-4-(methylsulfamoyl)phenyl]hydrazinylidene]-3-oxo-N-(2-oxo-1,3-dihydrobenzimidazol-5-yl)naphthalene-2-carboxamide CAS.NO:51920-12-8


Related News: With the improvement of domestic GMP management level, the increase of process development capabilities and international certification experience, China has already possessed the conditions for developing characteristic APIs.2,3-Diethyl-5-methylpyrazine CAS:18138-04-0 Profitability continued to improve. The company’s comprehensive gross profit margin for the first three quarters was 36.06%, a year-on-year increase of 3.44 percentage points. Since this year, the company’s profitability has remained at a relatively high level. On the one hand, due to the decline in the trading business with lower profitability, the proportion has declined.10,10-dimetilatrona CAS:5447-86-9 Profitability continued to improve. The company’s comprehensive gross profit margin for the first three quarters was 36.06%, a year-on-year increase of 3.44 percentage points. Since this year, the company’s profitability has remained at a relatively high level. On the one hand, due to the decline in the trading business with lower profitability, the proportion has declined.3268-49-3 Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.

Related Products
Product Name
(3aS,6aR)-4-methoxy-3a,4,6,6a-tetrahydro-3H-furo[2,3-c]furan-2-one View Details
2-Bromo-3,5-dichloropyridine View Details
6-methylpyridin-2-amine View Details
Dirucotide manufacturer Vitamin A manufacturer 4-Amino-1-methyl-3-propyl-1H-pyrazole-5-carboxamide manufacturer 1,3-BIS(ISOCYANATOMETHYL)CYCLOHEXANE manufacturer 5-Methoxy-2-mercaptobenzimidazole manufacturer